International Journal of Drug Delivery Technology
Volume 15, Issue 1

CRISPR/CAS9 And Gene Editing in Drug Delivery: Emerging Delivery Systems for Gene Therapy and Genome

Patil G R*, Varma S K

Datta Meghe Institute of Higher Education and Research, Wardha, India 

Received: 30th Nov, 2024; Revised: 8th Jan, 2024; Accepted: 21st Feb, 2024; Available Online: 25th Mar, 2025

ABSTRACT

GENETIC EDITING: CRISPR/Cas9 technologies have revolutionised genome editing. They offer unmatched precision, speed, and versatility. Familiar with the immune system of bacteria, it is now a powerful tool. It treats genetic diseases, infectious diseases, and cancer. And even as an omen, its clinical effectiveness demands reliable, precise means of administration. These systems have created viral and non-viral platforms. The list includes: lipid nanoparticles (LNPs), viral vectors (AAVs), and polymeric nanoparticles. New delivery technologies, like SORT LNPs and VLPs, have improved targeting. They offer better therapy and fewer off-target effects.Nonetheless, significant obstacles remain. Delivery efficiencies, immunogenicity and scalability are huge hurdles to wide-scale clinical deployment. To reduce these difficulties, we can develop small Cas variants like Cas12a. We can also engineer guide RNAs (gRNAs) for better precision and fewer off-target effects. There are promising prospects. They come from AI-optimised, hybrid delivery platforms. They are virally-free and non-viral. The FDA's approval of CRISPR drugs for sickle cell disease shows their potential to cure some incurable diseases. Trials now include rare genetic diseases, cancers and metabolic disorders. No matter how big it is, production scale and cost are a bottleneck. We still need better manufacturing and quality control practices. This review examines the latest advances in CRISPR/Cas9 delivery methods. It covers the barriers to clinical use and the future of this groundbreaking technology. CRISPR/Cas9 could revolutionise medicine. It may provide treatments that target the root causes of diseases. It could overcome current limits and use new discoveries.

Keywords: CRISPR/Cas9, gene editing, drug delivery, lipid nanoparticles, gene therapy, genome editing, viral vectors

How to cite this article: Patil G R, Varma S K. CRISPR/CAS9 And Gene Editing in Drug Delivery: Emerging Delivery Systems for Gene Therapy and Genome. International Journal of Drug Delivery Technology. 2025;15(1):335-41. doi: 10.25258/ijddt.15.1.46

REFERENCES

  1. Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Advanced drug delivery reviews. 2021 Sep 1;176:113891.
  2. Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, Zhang H, Cui W. Progress of delivery methods for CRISPR-Cas9. Expert opinion on drug delivery. 2022 Aug 3;19(8):913-26.
  3. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. Journal of controlled release. 2017 Nov 28;266:17-26.
  4. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. Journal of controlled release. 2017 Nov 28;266:17-26.
  5. Chen F, Alphonse M, Liu Q. Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2020 May;12(3):e1609.
  6. Zhou L, Yao S. Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications. Molecular Biomedicine. 2023 Apr 7;4(1):10.
  7. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. American Society of Clinical Oncology Educational Book. 2013 Jan 1;33(1):118-25.
  8. Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances. 2020 Nov 18;6(47):eabc9450.
  9. Han JP, Kim M, Choi BS, Lee JH, Lee GS, Jeong M, Lee Y, Kim EA, Oh HK, Go N, Lee H. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Science advances. 2022 Jan 21;8(3):eabj6901.
  10. Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Frontiers in Bioengineering and Biotechnology. 2022 May 12;10:895713.
  11. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
  12. Caprifico AE, Foot PJ, Polycarpou E, Calabrese G. Advances in chitosan-based CRISPR/Cas9 delivery systems. Pharmaceutics. 2022 Sep 1;14(9):1840.
  13. Lyu P, Lu B. New advances in using virus-like particles and related technologies for eukaryotic genome editing delivery. International Journal of Molecular Sciences. 2022 Aug 6;23(15):8750.
  14. Ikwuagwu B, Tullman-Ercek D. Virus-like particles for drug delivery: a review of methods and applications. Current Opinion in Biotechnology. 2022 Dec 1;78:102785.
  15. Wichmann M, Maire CL, Nuppenau N, Habiballa M, Uhde A, Kolbe K, Schröder T, Lamszus K, Fehse B, Głów D. Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs. International Journal of Molecular Sciences. 2023 Jul 13;24(14):11399.
  16. Tan X. Gag-derived VLPs and the delivery of CRISPR-Cas9 system in Gene and Cell Therapies. Highlights in Science, Engineering and Technology. 2023 Mar 21;36:1511-6.
  17. Chen K, Jiang S, Hong Y, Li Z, Wu YL, Wu C. Cationic polymeric nanoformulation: Recent advances in material design for CRISPR/Cas9 gene therapy. Progress in Natural Science: Materials International. 2019 Dec 1;29(6):617-27.
  18. Verma R, Sahu R, Singh DD, Egbo TE. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections. InSeminars in cell & developmental biology 2019 Dec 1 (Vol. 96, pp. 44-52). Academic Press.
  19. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
  20. Kim M, Hwang Y, Lim S, Jang HK, Kim HO. Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9. Pharmaceutics. 2024 Sep 11;16(9):1197.
  21. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
  22. Singh D. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies. AAPS PharmSciTech. 2024 Jun 6;25(5):129.
  23. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells. 2020 Jul 2;9(7):1608.
  24. Bhattacharjee R, Jana A, Nandi A, Sinha A, Bhattacharjee A, Mitra S, Kar S, Dey A, Singh SK, Varma RS, Panda PK. Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical appliances: Current insights and perspectives. Materials & Design. 2022 Dec 1;224:111415.
  25. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. Journal of medical genetics. 2015 May 1;52(5):289-96.
  26. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
  27. Wang L, Chen Y, Liu X, Li Z, Dai X. The application of CRISPR/Cas9 technology for cancer immunotherapy: Current status and problems. Frontiers in Oncology. 2022 Jan 17;11:704999.
  28. Bhowmik P, Konkin D, Polowick P, Hodgins CL, Subedi M, Xiang D, Yu B, Patterson N, Rajagopalan N, Babic V, Ro DK. CRISPR/Cas9 gene editing in legume crops: Opportunities and challenges. Legume Science. 2021 Sep;3(3):e96.
  29. Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V. Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives. International journal of molecular sciences. 2021 Mar 24;22(7):3327.
  30. Chen Y, Ping Y. Development of CRISPR/Cas delivery systems for in vivo precision genome editing. Accounts of Chemical Research. 2023 Aug 1;56(16):2185-96.
  31. Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone SN, Masoodi T, Chauhan R, Maacha S, Bagga P, Dhawan P. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. Journal of translational medicine. 2022 Nov 18;20(1):534.
  32. Foley RA, Sims RA, Duggan EC, Olmedo JK, Ma R, Jonas SJ. Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. Frontiers in Bioengineering and Biotechnology. 2022 Sep 26;10:973326.
  33. Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert opinion on drug delivery. 2018 Sep 2;15(9):905-13.